Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 5/20 | 0.34 |
| ▸ | FAAH | O00519 | 2/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.33 |
| ▸ | MGLL | Q99685 | 2/20 | 0.33 |
| ▸ | TYMP | P19971 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | HEXA | P06865 | 1/20 | 0.30 |
| ▸ | HEXB | P07686 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7515622 | 0.82 | SMN1; SMN2 (0.34) | SMN1; SMN2CNR1 | |
| SCHEMBL7528765 | 0.81 | PTGS1 (0.42) | PTGS1PTGS2 | |
| SCHEMBL7529003 | 0.81 | TYMP (0.36) | SMN1; SMN2TYMPRAB9A | |
| SCHEMBL14923261 | 0.81 | CNR1 (0.33) | CNR1FAAHPTGS1PTGS2MGLL | |
| SCHEMBL7517762 | 0.79 | RAB9A (0.39) | SMN1; SMN2TYMPRAB9A | |
| SCHEMBL7537328 | 0.79 | KAT2B (0.36) | SMN1; SMN2RAB9A | |
| SCHEMBL7524740 | 0.79 | TYMP (0.37) | SMN1; SMN2TYMPRAB9A | |
| SCHEMBL7526190 | 0.79 | SMN1; SMN2 (0.32) | SMN1; SMN2CNR1FAAHRAB9A | |
| SCHEMBL7525031 | 0.79 | EPHX1 (0.42) | RAB9A | |
| SCHEMBL7537236 | 0.79 | RAB9A (0.34) | SMN1; SMN2CNR1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005058311-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | SCHERING CORPORATION (US) | 2005-06-30 | — | — | WO | disclosed |